Wells Fargo Upgrades Relay Therapeutics (RLAY) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailGet Alerts RLAY Hot Sheet
Price: $16.28 -5.9%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Join SI Premium – FREE
Wells Fargo analyst Eva Fortea Verdejo upgraded Relay Therapeutics (NASDAQ: RLAY) from Equal Weight to Overweight with a price target of $13.00.
For an analyst ratings summary and ratings history on Relay Therapeutics click here. For more ratings news on Relay Therapeutics click here.
Shares of Relay Therapeutics closed at $7.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Upgrades South Indian Bank (SIB:IN) to Buy (1)
- Bernstein SocGen Group Reiterates Underperform Rating on Mankind Pharma Ltd (MANKIND:IN)
- RBC: 'We believe $480/share is a price at which Tesla shareholders should be receptive to a deal'
Create E-mail Alert Related Categories
UpgradesRelated Entities
Wells Fargo, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
